Yourgene Health PLC Appointment of Joint Broker (4965U)

TIDMYGEN

RNS Number : 4965U

Yourgene Health PLC

29 July 2020

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Appointment of Joint Broker

Manchester, UK - 29 July 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as joint broker with immediate effect.

Cairn Financial Advisors LLP will continue as the Company's nominated adviser and Stifel Nicolaus Europe Limited will continue as the Company's joint broker.

 
Yourgene Health plc                                                  Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                              investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
 
Cairn Financial Advisers LLP (NOMAD)                                 Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
 
N+1 Singer (Joint Corporate Broker)                                  Tel: +44 (0)207 496 3000 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
 
Walbrook PR Ltd (Media and Investor       Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                               Mob: 07980 541 893 / Mob: 07584 
                                                                                      391 303

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and precision medicine. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPBGGDRIUDDGGC

(END) Dow Jones Newswires

July 29, 2020 07:05 ET (11:05 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024